Introduction to prednisolone
Prednisolone is a synthetic corticosteroid medication that belongs to the glucocorticoid class of steroid hormones. As the active metabolite of prednisone, prednisolone exerts potent anti-inflammatory and immunosuppressive effects that make it one of the most widely prescribed medications in medicine. Since its introduction into clinical practice in the 1950s, prednisolone has become an indispensable therapeutic agent for a vast array of medical conditions characterized by inflammation, autoimmunity, and allergic dysregulation. The drug works by mimicking the actions of cortisol, the body’s natural stress hormone, but with greater potency and a longer duration of action. Prednisolone’s ability to rapidly suppress inflammation and modulate immune responses has made it a foundation of treatment for conditions ranging from asthma and allergic reactions to rheumatoid arthritis, inflammatory bowel disease, and organ transplantation rejection prophylaxis. Despite the development of more targeted biologic therapies in recent decades, prednisolone remains a first-line treatment for many inflammatory conditions due to its broad-spectrum efficacy, rapid onset of action, and favorable cost profile. For patients requiring this versatile medication, Happy Family Store provides a reliable source for purchasing prednisolone over the counter.
Mechanism of action
The therapeutic effects of prednisolone are mediated through complex genomic and nongenomic mechanisms that ultimately converge on the suppression of inflammatory and immune responses. At the cellular level, prednisolone diffuses across cell membranes and binds to the glucocorticoid receptor, a cytoplasmic protein that, upon ligand binding, translocates to the cell nucleus. Once in the nucleus, the activated glucocorticoid-receptor complex interacts with specific DNA sequences called glucocorticoid response elements located in the promoter regions of target genes. This interaction can either enhance or suppress the transcription of these genes, depending on the specific cellular context and the nature of the gene involved.
The anti-inflammatory effects of prednisolone are primarily attributed to a process called transrepression, wherein the activated glucocorticoid receptor interferes with the activity of pro-inflammatory transcription factors such as nuclear factor-kappa B and activator protein-1. NF-kB is a master regulator of the inflammatory response, controlling the expression of hundreds of genes involved in inflammation including cytokines such as interleukins IL-1, IL-2, IL-6, and tumor necrosis factor-alpha, chemokines, adhesion molecules, and enzymes such as cyclooxygenase-2 and inducible nitric oxide synthase. By blocking NF-kB and AP-1 activity, prednisolone effectively shuts down the production of these inflammatory mediators at the transcriptional level. This mechanism explains the broad anti-inflammatory effects of corticosteroids and their efficacy across diverse inflammatory conditions.
In addition to transrepression, prednisolone also exerts effects through transactivation, wherein the glucocorticoid-receptor complex directly activates the transcription of anti-inflammatory genes. These include genes encoding lipocortin-1, which inhibits phospholipase A2 and thereby reduces the production of prostaglandins and leukotrienes; interleukin-10, an anti-inflammatory cytokine; and I-kappaB-alpha, an endogenous inhibitor of NF-kB. The balance between transrepression and transactivation effects contributes to both the therapeutic efficacy and the side effect profile of prednisolone, with many adverse effects being attributed to excessive transactivation.
Beyond these genomic mechanisms, prednisolone also produces rapid nongenomic effects that occur within minutes of administration, too quickly to be mediated by changes in gene expression. These effects involve direct interactions of the glucocorticoid receptor with cellular signaling pathways, including activation of endothelial nitric oxide synthase, modulation of PI3K and MAPK signaling, and effects on membrane fluidity and ion transport. These rapid nongenomic effects contribute to the immediate clinical benefits seen with high-dose corticosteroid therapy in acute conditions such as severe asthma exacerbations and anaphylaxis.
The pharmacokinetic profile of prednisolone supports its clinical versatility. After oral administration, prednisolone is rapidly and completely absorbed from the gastrointestinal tract, with peak plasma concentrations achieved within one to two hours. Unlike prednisone, which requires hepatic conversion to its active form by the enzyme 11-beta-hydroxysteroid dehydrogenase, prednisolone is the active metabolite itself and does not require metabolic activation. This makes prednisolone particularly suitable for patients with hepatic impairment who may not effectively convert prednisone. The drug is approximately 70 to 90 percent bound to plasma proteins, primarily corticosteroid-binding globulin and albumin. Prednisolone is metabolized in the liver, primarily by CYP3A4, and has an elimination half-life of approximately two to four hours, though its biological half-life is longer at 18 to 36 hours due to the prolonged duration of its genomic effects.
Therapeutic indications and uses
Respiratory conditions
Prednisolone plays a critical role for multiple respiratory diseases. In asthma, oral prednisolone is used for the treatment of acute exacerbations that are unresponsive to bronchodilators and inhaled corticosteroids. Short courses of high-dose prednisolone rapidly reduce airway inflammation, improve lung function, and prevent hospitalization. In chronic obstructive pulmonary disease, systemic corticosteroids such as prednisolone are used for acute exacerbations to speed recovery and reduce the risk of relapse. The drug is also used for sarcoidosis, where it suppresses the granulomatous inflammation that characterizes this multisystem disease. In idiopathic pulmonary fibrosis and other interstitial lung diseases, prednisolone is often used as part of combination therapy regimens, though its efficacy in these conditions is variable and must be weighed against the risks of long-term therapy.
Rheumatologic and musculoskeletal conditions
Prednisolone is used in rheumatology for its potent anti-inflammatory effects. In rheumatoid arthritis, low-dose prednisolone provides rapid symptom relief and may slow disease progression when used in combination with disease-modifying antirheumatic drugs. Higher doses are used for disease flares and for severe manifestations such as rheumatoid vasculitis. In polymyalgia rheumatica and giant cell arteritis, prednisolone is the treatment of choice, with patients typically requiring therapy for one to two years or longer. Systemic lupus erythematosus, dermatomyositis, polymyositis, and various forms of vasculitis are all treated with prednisolone, often at high doses or as pulse therapy for severe organ-threatening disease. Gout attacks respond rapidly to short courses of prednisolone in patients who cannot tolerate nonsteroidal anti-inflammatory drugs. Pseudogout, reactive arthritis, and other inflammatory arthropathies also benefit from corticosteroid therapy.
Gastrointestinal conditions
Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, is a major indication for prednisolone therapy. The drug is used for moderate to severe disease flares to induce remission, with doses typically tapered gradually over several weeks or months. In Crohn’s disease, prednisolone is effective for both ileal and colonic disease and can reduce the need for surgical intervention. In ulcerative colitis, it is used for extensive or severe disease, often in combination with mesalamine or biologic therapies. Prednisolone is also used in autoimmune hepatitis, eosinophilic esophagitis, and acute severe pancreatitis.
Dermatological conditions
A wide variety of skin diseases respond to prednisolone therapy. Severe atopic dermatitis, contact dermatitis, and drug hypersensitivity reactions often require systemic corticosteroid therapy when topical treatments are insufficient. Pemphigus vulgaris and bullous pemphigoid, potentially life-threatening autoimmune blistering diseases, require high-dose prednisolone as first-line therapy. Other conditions including severe psoriasis, erythema multiforme, Stevens-Johnson syndrome, and cutaneous vasculitis are also treated with systemic corticosteroids. The rapid anti-inflammatory effects of prednisolone provide symptomatic relief of itching, redness, and swelling while longer-term therapies take effect.
Allergic and immunologic conditions
Prednisolone is used for severe allergic reactions including anaphylaxis, angioedema, and severe drug allergies, typically as adjunctive therapy following epinephrine administration. In organ transplantation, prednisolone is a key component of immunosuppressive protocols used to prevent and treat graft rejection. The drug is also used for graft-versus-host disease following hematopoietic stem cell transplantation. In severe immunoglobulin E-mediated food allergies, short courses of prednisolone may be used during desensitization protocols.
Neurological conditions
In neurology, high-dose prednisolone is standard therapy for acute exacerbations of multiple sclerosis, where it speeds recovery from relapse and reduces the risk of persistent neurological deficits. The drug is also used in the treatment of cerebral edema associated with brain tumors, neurosurgical procedures, and certain infections. Myasthenia gravis exacerbations, acute transverse myelitis, optic neuritis, and various inflammatory neuropathies including Guillain-Barre syndrome are also treated with prednisolone in specific clinical contexts.
Hematological conditions
Prednisolone is an important agent in the treatment of various hematological malignancies and benign hematological disorders. In acute lymphoblastic leukemia, prednisolone is a core component of induction chemotherapy regimens. In Hodgkin and non-Hodgkin lymphomas, it is included in combination chemotherapy protocols. Immune thrombocytopenic purpura responds rapidly to prednisolone, with the drug increasing platelet counts through suppression of autoantibody production. Autoimmune hemolytic anemia, pure red cell aplasia, and hemophagocytic lymphohistiocytosis are also treated with corticosteroids.
Ophthalmic conditions
Various inflammatory eye diseases benefit from prednisolone therapy. Non-infectious uveitis, scleritis, episcleritis, and orbital inflammatory disease are commonly treated with oral prednisolone. The drug is also used for sympathetic ophthalmia, a rare inflammatory response to ocular trauma or surgery. While topical corticosteroid eye drops are preferred for anterior segment inflammation, systemic prednisolone is required for posterior uveitis, panuveitis, and orbital disease.
Renal conditions
In nephrology, prednisolone is used in the treatment of various glomerulonephritides including minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and lupus nephritis. The dose and duration of therapy depend on the specific histologic diagnosis and the severity of disease. In many cases, prednisolone is combined with other immunosuppressive agents such as cyclophosphamide or mycophenolate for optimal outcomes.
Dosage and administration
General dosing principles
The dosage of prednisolone must be individualized based on the condition being treated, its severity, the patient’s response, and the development of adverse effects. In general, the lowest effective dose should be used for the shortest duration necessary to achieve therapeutic goals. Dosing can be categorized into low-dose therapy (less than 7.5 mg daily), medium-dose therapy (7.5 to 30 mg daily), high-dose therapy (30 to 100 mg daily), and pulse therapy (250 to 1000 mg daily for one to five days). The choice of dosing strategy depends on the acuity and severity of the condition.
Acute conditions
For acute exacerbations of inflammatory conditions, higher initial doses are used to rapidly gain control, followed by a taper as the condition improves. For example, an acute asthma exacerbation may be treated with 40 to 60 mg of prednisolone daily for five to seven days, often without the need for a taper when treatment duration is short. For acute flares of rheumatoid arthritis, starting doses of 10 to 20 mg daily may be used, with rapid tapering once symptoms improve. For severe acute conditions such as acute lupus nephritis or pemphigus vulgaris, starting doses of 60 to 100 mg daily may be required.
Chronic conditions
For chronic inflammatory conditions requiring long-term therapy, the goal is to use the lowest effective maintenance dose. Many patients with rheumatoid arthritis or polymyalgia rheumatica can be maintained on doses of 5 to 10 mg daily. For conditions requiring prolonged therapy such as giant cell arteritis, starting doses of 40 to 60 mg daily are gradually tapered over months to years, with the taper guided by clinical response and inflammatory markers.
Dose tapering
Discontinuation of prednisolone after prolonged use requires gradual dose tapering to allow recovery of the hypothalamic-pituitary-adrenal axis, which becomes suppressed during corticosteroid therapy. The taper schedule depends on the dose and duration of therapy. Patients who have been on therapy for less than three weeks can often discontinue treatment abruptly without significant HPA axis suppression. For patients on longer courses, the taper should be gradual, typically reducing the dose by 2.5 to 5 mg every one to four weeks, with slower tapering at lower doses. A typical taper might involve reducing the daily dose by 2.5 mg every week until a dose of 10 mg daily is reached, then slowing to reductions of 1 mg every one to two weeks until discontinuation.
Administration instructions
Prednisolone tablets should be taken with food to minimize gastrointestinal irritation. The medication is usually taken in the morning to mimic the natural diurnal rhythm of cortisol secretion and to minimize insomnia and other sleep disturbances. Single daily dosing is generally preferred for maintenance therapy, while twice-daily or three-times-daily dosing may be necessary for acute conditions requiring higher doses. Patients should be advised not to discontinue the medication abruptly without consulting their healthcare provider, especially after prolonged use. For patients who have difficulty swallowing tablets, prednisolone is also available as an oral solution in some formulations.
Side effects and adverse reactions
Metabolic and endocrine effects
The adverse effects of prednisolone are numerous and relate primarily to the drug’s glucocorticoid and mineralocorticoid activities. Metabolic effects include hyperglycemia and diabetes mellitus, which occurs due to increased gluconeogenesis and reduced insulin sensitivity. The risk of corticosteroid-induced diabetes is dose-dependent, and pre-diabetic patients are at highest risk. Weight gain with central obesity is common, as is redistribution of body fat leading to the characteristic cushingoid appearance with moon facies, buffalo hump, and supraclavicular fat pads. Dyslipidemia with elevated triglycerides and LDL cholesterol may develop. Adrenal suppression is an expected effect of prolonged therapy and requires gradual dose tapering for recovery.
Musculoskeletal effects
Osteoporosis is one of the most significant adverse effects of long-term prednisolone therapy. The drug inhibits bone formation, promotes bone resorption, and reduces calcium absorption from the intestine, leading to decreased bone mineral density and increased fracture risk. The effect is particularly pronounced in trabecular bone such as the vertebrae and femoral neck. All patients on doses equivalent to 7.5 mg of prednisolone daily for three months or longer should receive calcium and vitamin D supplementation and be considered for bisphosphonate therapy. Myopathy with proximal muscle weakness is another common musculoskeletal effect, particularly with high doses and prolonged use.
Gastrointestinal effects
Gastrointestinal adverse effects include dyspepsia, gastritis, and peptic ulcer disease. The risk of ulcers is increased when prednisolone is combined with nonsteroidal anti-inflammatory drugs. Pancreatitis has been reported but is rare. The drug may also mask the symptoms of gastrointestinal perforation, a potentially life-threatening complication that can go unrecognized in patients on corticosteroids. Esophageal candidiasis and other gastrointestinal infections may occur due to immunosuppression.
Cardiovascular effects
Prednisolone therapy is associated with an increased risk of hypertension due to sodium retention, increased vasoconstriction, and enhanced sensitivity to vasopressors. Fluid retention with peripheral edema is common, particularly with higher doses or in patients with preexisting cardiac or renal disease. Long-term therapy increases the risk of atherosclerosis, myocardial infarction, stroke, and heart failure. The drug may also cause dysrhythmias, particularly at high doses or with rapid intravenous administration.
Central nervous system effects
Corticosteroid therapy can produce a range of neuropsychiatric effects. Insomnia and mood disturbances including euphoria, irritability, and anxiety are common, particularly at higher doses. More serious psychiatric effects including depression, mania, psychosis, and delirium can occur, especially in patients with preexisting psychiatric disorders or at very high doses. Cognitive effects including memory impairment and difficulty concentrating have been reported. Pseudotumor cerebri with increased intracranial pressure is a rare but serious complication.
Immunologic effects
As an immunosuppressant, prednisolone increases the risk of infections, including bacterial, viral, fungal, and parasitic infections. Common infections include respiratory tract infections, urinary tract infections, and cutaneous infections. Reactivation of latent infections is a significant concern, particularly reactivation of tuberculosis, hepatitis B, and varicella-zoster virus. Patients on chronic corticosteroid therapy should receive appropriate vaccinations including pneumococcal and influenza vaccines, while live vaccines should be avoided during high-dose therapy.
Ophthalmologic effects
Long-term prednisolone therapy increases the risk of posterior subcapsular cataracts in a dose-dependent manner. Glaucoma may also develop or worsen due to increased intraocular pressure. Regular ophthalmologic monitoring is recommended for patients on prolonged therapy. Exophthalmos may worsen in patients with Graves’ ophthalmopathy, and central serous chorioretinopathy has been associated with corticosteroid use.
Dermatologic effects
Cutaneous adverse effects include skin thinning and fragility, easy bruising, striae, impaired wound healing, and acne. Hirsutism and hypertrichosis may occur. The skin becomes more susceptible to infections including candidiasis and herpes simplex. Perioral dermatitis and rosacea may be exacerbated by corticosteroid therapy. These effects are primarily cosmetic but can be distressing for patients.
Contraindications and precautions
Absolute contraindications
Prednisolone is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Systemic fungal infections are an absolute contraindication due to the risk of disseminated infection in the setting of immunosuppression. Live or live-attenuated vaccines should not be administered to patients receiving immunosuppressive doses of corticosteroids. The drug is also contraindicated in patients with cerebral malaria and in patients who have recently received intrathecal chemotherapy.
Relative contraindications and precautions
Caution is required when using prednisolone in patients with various conditions. In patients with diabetes mellitus, blood glucose levels must be closely monitored and antidiabetic medications may need adjustment. Patients with hypertension require regular blood pressure monitoring and appropriate antihypertensive therapy. In patients with a history of tuberculosis, prednisolone may cause reactivation of latent disease, and prophylactic antituberculosis therapy may be indicated. Patients with osteoporosis should be evaluated and treated for bone loss. The drug should be used cautiously in patients with diverticulitis, fresh intestinal anastomoses, active peptic ulcer disease, renal insufficiency, hepatic impairment, and congestive heart failure.
Pregnancy and lactation
Prednisolone is classified as Pregnancy Category C in older classification systems. Animal studies have shown teratogenic effects including cleft palate, but adequate human studies are lacking. The drug crosses the placenta but is partially inactivated by placental enzymes, resulting in lower fetal exposure compared to maternal levels. Prednisolone should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the fetus. The drug is excreted in breast milk but in concentrations that are unlikely to cause clinically significant effects in nursing infants at moderate maternal doses. However, infants should be monitored for growth and development if the mother is on prolonged high-dose therapy.
Drug interactions
Pharmacokinetic interactions
Prednisolone is metabolized primarily by CYP3A4, and drugs that inhibit or induce this enzyme can affect prednisolone concentrations. CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, and grapefruit juice can increase prednisolone exposure and the risk of adverse effects. CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, phenobarbital, and St. John’s wort can decrease prednisolone levels and reduce efficacy, potentially requiring dose adjustments. Estrogen-containing oral contraceptives may increase prednisolone levels by reducing its clearance.
Pharmacodynamic interactions
Nonsteroidal anti-inflammatory drugs and salicylates should be used with caution in patients taking prednisolone due to additive effects on gastrointestinal ulceration and bleeding. The combination of corticosteroids with NSAIDs increases the risk of peptic ulcer disease and gastrointestinal hemorrhage. Anticoagulants such as warfarin may have altered effects when combined with prednisolone, requiring more frequent INR monitoring. The anticoagulant effects of warfarin may be either enhanced or reduced by corticosteroids. Potassium-depleting diuretics such as loop diuretics and thiazide diuretics may increase the risk of hypokalemia when combined with prednisolone, which has some mineralocorticoid activity. The hypokalemia risk is further increased by concurrent therapy with amphotericin B or carbenoxolone.
Immunologic interactions
Immunosuppressant medications including methotrexate, cyclosporine, tacrolimus, and biologic agents have additive immunosuppressive effects when combined with prednisolone, increasing the risk of infections. Vaccination with live vaccines is contraindicated during high-dose corticosteroid therapy, and the response to inactivated vaccines may be diminished. Patients should complete all recommended vaccinations before initiating corticosteroid therapy when possible.
Special populations
Pediatric use
Children treated with long-term prednisolone require special consideration. Growth suppression is a significant concern, with the drug reducing bone growth and causing a dose-dependent decrease in final adult height. The effect is most pronounced with high doses and prolonged therapy. Alternate-day dosing regimens may reduce growth suppression while maintaining therapeutic efficacy. Children should have their growth parameters regularly monitored, and pediatric endocrinology consultation should be considered for those requiring long-term therapy. The risk of osteoporosis in children is also significant, and adequate calcium and vitamin D intake should be ensured.
Geriatric use
Elderly patients are at increased risk for many of the adverse effects of prednisolone. Osteoporosis and fracture risk are more significant in this population, which already has reduced bone density due to aging. Glucose intolerance and new-onset diabetes are more common in elderly patients receiving corticosteroids. Hypertension, fluid retention, and cardiac effects are more problematic in older adults with preexisting cardiovascular disease. Neuropsychiatric effects including confusion, delirium, and mood disturbances may be more pronounced in elderly patients. Lower starting doses and careful monitoring are recommended.
Hepatic and renal impairment
Patients with severe hepatic impairment may have reduced clearance of prednisolone, although the effect is less pronounced than with prednisone since prednisolone does not require hepatic activation. Dose reduction may still be necessary in patients with significant liver disease. In patients with renal impairment, the mineralocorticoid effects of prednisolone may exacerbate fluid retention and hypertension, particularly in patients with preexisting renal disease. The elimination of prednisolone metabolites may be impaired in severe renal failure, though the clinical significance is limited.
Clinical pharmacology in depth
Prednisolone has the molecular formula C21H28O5 and a molecular weight of 360.4 g/mol. It is a synthetic analog of cortisol with modifications that enhance its glucocorticoid potency while reducing mineralocorticoid activity. The addition of a double bond in the A ring of the steroid nucleus creates prednisolone from hydrocortisone, increasing glucocorticoid potency approximately four-fold. The drug’s anti-inflammatory potency is approximately four to five times that of cortisol and 1.2 to 1.5 times that of prednisone. Prednisolone has weak mineralocorticoid activity, approximately 0.8 times that of cortisol, which is less than that of prednisone.
The oral bioavailability of prednisolone is approximately 80 to 100 percent, with the drug being well absorbed from the gastrointestinal tract. The volume of distribution is approximately 0.5 to 1.0 L/kg, reflecting distribution into total body water. Prednisolone is bound to plasma proteins, primarily corticosteroid-binding globulin, with the free fraction increasing at higher drug concentrations due to saturation of CBG binding. The drug is eliminated primarily through hepatic metabolism, with only about 10 percent excreted unchanged in urine. The major metabolic pathways include reduction of the C20 ketone group and the C4-C5 double bond, hydroxylation, and conjugation with glucuronic acid and sulfate.
Patient education and counseling
Patients prescribed prednisolone require comprehensive education about their medication. They should be informed that the drug is a potent anti-inflammatory medication that suppresses the immune system and should be taken exactly as prescribed. Patients should understand the importance of not abruptly discontinuing the medication, particularly after prolonged use, due to the risk of adrenal insufficiency. The signs and symptoms of adrenal insufficiency, including fatigue, weakness, nausea, vomiting, abdominal pain, and hypotension, should be reviewed. Patients should be advised to carry a steroid card or wear a medical alert bracelet indicating that they are taking corticosteroids, especially if they are on long-term therapy or doses equivalent to 10 mg of prednisolone or more daily.
Patients should be counseled about the importance of taking the medication with food to reduce gastrointestinal irritation. The morning dosing schedule helps mimic natural cortisol rhythm and minimize sleep disturbances. Patients should be advised to avoid close contact with individuals who have active infections, particularly chickenpox and measles, and to seek medical attention promptly if exposed. All healthcare providers, including dentists, should be informed about corticosteroid therapy, as dose adjustments may be needed during periods of stress or illness. Patients should be encouraged to maintain adequate calcium and vitamin D intake and to participate in weight-bearing exercise to minimize bone loss. Regular monitoring including blood glucose, blood pressure, bone density, and eye examinations should be discussed.
For patients who purchase prednisolone from Happy Family Store, it is important to follow the dosing and administration instructions provided and to consult with a healthcare professional regarding appropriate monitoring and follow-up care.
Frequently asked questions
What is the difference between prednisone and prednisolone?
Prednisone is a prodrug that is converted by the liver into prednisolone, the active form. Prednisolone does not require hepatic conversion and is therefore preferred in patients with liver disease. Equipotent doses of the two drugs produce similar therapeutic effects. The conversion is mediated by the enzyme 11-beta-hydroxysteroid dehydrogenase type 1, which is abundant in the liver.
How long can i take prednisolone safely?
The safety of prednisolone depends on the dose and duration of therapy. Short courses up to three weeks can generally be stopped without tapering and are associated with minimal long-term risks. Long-term therapy requires careful monitoring and preventive measures for osteoporosis, weight gain, diabetes, and other adverse effects. The goal is always to use the lowest effective dose for the shortest duration necessary.
Can prednisolone cause weight gain?
Weight gain is a common and dose-dependent side effect of prednisolone therapy. The drug causes increased appetite, fluid retention, and redistribution of body fat to the face, neck, and trunk. Dietary counseling and regular exercise can help mitigate weight gain. Some patients may benefit from consultation with a dietitian.
Is prednisolone safe for children?
Prednisolone can be used in children for appropriate indications, but long-term use raises concerns about growth suppression, osteoporosis, and other adverse effects. Growth should be carefully monitored, and the lowest effective dose should be used. Alternate-day dosing may reduce the impact on growth while maintaining therapeutic efficacy.
Can i drink alcohol while taking prednisolone?
Alcohol should be limited or avoided while taking prednisolone. The combination of alcohol and corticosteroids can increase the risk of gastrointestinal irritation and bleeding, and alcohol may worsen some corticosteroid-related side effects such as fluid retention and glucose intolerance. Patients should consult their healthcare provider about alcohol consumption while on corticosteroid therapy.
Does prednisolone interact with other medications?
Prednisolone interacts with many medications. Important interactions include NSAIDs which increase the risk of gastrointestinal bleeding, anticoagulants which require closer monitoring, and CYP3A4 inhibitors or inducers which can alter prednisolone levels. Patients should provide their healthcare provider with a complete list of all medications they are taking.
What should i do if i miss a dose of prednisolone?
If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double doses to compensate for a missed dose. Consistency in dosing is important, particularly for patients on maintenance therapy.
Can prednisolone cause insomnia?
Insomnia and sleep disturbances are common side effects of prednisolone therapy. Taking the medication in the morning can help minimize sleep disruption. Patients who experience persistent insomnia should discuss this with their healthcare provider, who may recommend dose adjustments, timing strategies, or other interventions.
Storage and handling
Prednisolone tablets should be stored at room temperature between 20 and 25 degrees Celsius, away from moisture, heat, and direct light. The medication should be kept in its original container with the cap securely tightened. All medications should be kept out of reach of children and pets. Expired or unused medication should be disposed of properly according to local regulations, ideally through pharmacy take-back programs.